Drugs / XNW27011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06792435 | Jul 2023 → Jun 2025 overdue | biliary tract cancer, colorectal cancer, gastric carcinoma, gastroesophageal junction adenocarcinoma +3 | Evopoint Biosciences Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-05-30 | Astellas Pharma Inc | Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2 astellas.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XNW27011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06792435 ↗ |